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Background: Diabetic nephropathy (DN) is the major complication of diabetes; proteinuria is the hall mark of DN.
Currently, the treatment for proteinuria is mainly limited to angiotensin converting enzyme (ACE) inhibitors or
angiotensin II receptor blockers (ARBs). According to Traditional Chinese Medicine (TCM) theory, Chinese medicinals
‘securing essence and tonifying the kidney’ may be appropriate for proteinuria. The most promising Chinese
medicinals and formulae are introduced in the present study to form a potent formula for DN proteinuria. To make
oral administration convenient, the formula will be processed in the form of granules.
Methods/design: A randomized, multi-center pilot trial will be conducted. Forty eight participants with DN will be
randomly assigned to one of four treatment groups:
1. A granule group, at 10 grams, three times daily (G10 group, n = 12);
2. A granule group, at 20 grams, three times daily (G20 group, n = 12);
3. A decoction group (D group, n = 12); and
4. An irbesartan group (Aprovel group, n = 12).
The following outcome measures will be used: the percentage change of the albumin-to-creatinine ratio; and the
changes in serum creatinine, glomerular filtration rate, fasting plasma glucose and hemoglobulin from baseline to
the end of the trial.
Discussion: It is notable that most published clinical trials which assessed the efficacy of TCM on DN were of poor
methodology and, therefore, their results have been invalidated. It is necessary to carry out well-designed clinical
trials to provide sound evidence. The present trial is a study with potentially great value, for it will provide the
parameters for future randomized, placebo-controlled, clinical trials with large sample sizes.
Trial registration: The trial is registered on the Chinese Clinical Trial Registry: ChiCTR-TRC-12002718
(http://www.chictr.org/cn/proj/show.aspx?proj=3820).
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The prevalence of diabetic nephropathy (DN) in China
is not very clear; however, in Beijing, the city which has
the best medical service in China, the incidence of DN
in patients with type 2 diabetes is 35.7% and that of
microalbuminuria is 13.6% [1].* Correspondence: zhongsen6606@163.com
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reproduction in any medium, provided the orIn Traditional Chinese Medicine (TCM) theory, the
kidney is a paramount organ. It stores essence and the
essence transforms Qi and produces blood. In addition,
the kidney is the source of genuine Yin and genuine Yang.
It is called ‘the prenatal base of life’ in TCM textbooks [2].
In the TCM system, there are many Chinese medicinals
classified as tonifying and replenishing medicinals. Many
of them have the effects of replenishing Qi of the kidney
or tonifying kidney Yang.
We have known that DN is the major complication of
diabetes and proteinuria is the hallmark of DN. DN isThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(UAE) in the absence of other renal diseases, which is
categorized into stages according to the level of UAE,
that is, microalbuminuria (30 to 299 mg/24 hours) and
macroalbuminuria (300 mg/24 hours or greater) [3].
Currently, the treatment for proteinuria is largely limited
to angiotensin converting enzyme (ACE) inhibitors or
angiotensin II receptor blockers (ARBs) [4]. Although
the clinical beneficial effects of many ACE inhibitors or
ARBs have been established [5], the efforts of looking for
new drugs for DN that involve reducing proteinuria never
stop. For example, many researchers investigated astragalus
for the treatment of DN and the results seemed intriguing.
Zhang et al. [6] systematically reviewed published animal
experiments that had assessed the renal protective effects
of astragalus in diabetic rat models. Their results showed
significant beneficial effects of astragalus involving
improved fasting blood glucose levels, glomerular filtration
rate (GFR), urinary albumin excretion rate, and thickness of
the glomerular basement membrane. Hong and co-workers
[7] reported that astragalus might ‘play protective
roles in diabetic nephropathy through multiple pathways
at the gene level’.
Is TCM really able to lower proteinuria in patients
with DN? Current evidence has tried to address this
issue, but the picture remains unclear [8]. The present
research looks at the DN-lowering proteinuria effect of
TCM to answer this question. To evaluate the effects of
TCM accurately, the most promising Chinese medicinals
and formulae are used in the present study to form a potent
formula for the treatment of proteinuria of DN.
Because proteinuria, in TCM theory, results from the
leakage of the essence of the human body due to an
insufficiency of the kidney, it is promising to look for
Chinese medicinals that secure the essence and tonify
the kidney for the treatment of proteinuria. A typical
herb that secures essence and tonifies the kidney is used
in the present study, Flastem Milkvetch Seed. A famous
classical formula securing the essence and tonifying the
kidney is also introduced in the present study for the
treatment of proteinuria (Water-land Two Elixirs). It
consists of two Chinese medicinals, Gordon Euryale
Seed and Cherokee Rose Fruit. The first ingredient is
grown in water and the second one is grown on land, which
is the reason why it is named ‘Water-land.’ This formula is
very effective for treating conditions such as spermatorrhea
and enuresis [9]. However, only securing essence is not
enough; because Yin/Yang has been damaged, it is essential
to repair the balance between them.
There is a therapeutic strategy in TCM theory, namely,
using ‘cool’ and ‘warm’ herbs together to balance Yin/Yang;
this strategy is introduced in the present study. As the
most conspicuous topic in the area of TCM treatment for
DN, astragalus may be a very potent Chinese medicinal forproteinuria; therefore, it is also used in the present study.
Both basic and clinical studies have demonstrated that
astragalus could exert beneficial effects on DN
[10-12]. An in vitro study investigated the effect of
calycosin and calycosin-7-O-β-D-glucoside. These two
major isoflavonoids in astragalus were tested with
high glucose-induced rat mesangial cell proliferation
and advanced glycation end product (AGE)-induced
human glomerular endothelial cell apoptosis. The results
suggested that both isoflavonoids had a significant thera-
peutic potential to modulate the development and/or pro-
gression of DN [10]. Zhang and his co-workers studied the
effects of astragalus polysaccharide (APS), an aqueous
extract from the astragalus membranaceus roots, on gene
expressions of nuclear factor-kappaB (NF-kappaB) and an
inhibitory protein of NF-kappaB (IkappaB) in experimental
DN rats induced by streptozotocin. The results showed that
APS improved proteinuria and renal function and that the
mRNA level of NF-kappaB in renal cortex was decreased
and IkappaB mRNA expression was raised by APS [11]. A
randomized controlled trial showed that astragalus, in
combination with captopril, could significantly reduce UAE
[12]. However, astragalus is an herb of warm properties and
has the capacity to upset the balance of Yin/Yang. Coptidis,
is an herb of cool properties and is used to counteract the
potential harm caused by astragalus. Coptidis is used for
proteinuria because not only does it have centuries of
practice-based recognition as a reliable TCM remedy for
diabetes mellitus but its potential as a treatment for DN
has been established in recent evidence-based supportive
research. Liu et al. [13] evaluated the effects of compound
Rhizoma Coptidis capsule (CRCC) on early DN in rats
induced by streptozotocin. Their results showed that CRCC
could reduce the levels of fasting plasma glucose (FPG),
blood urea nitrogen (BUN), serum creatinine (Scr), protein-
uria, the expression of transforming growth factor-beta1
and IV-C proteins, and alleviate pathological lesions in
renal tissue of diabetic rats with nephropathy.
As a result, five Chinese medicinals are used in the
present study for the treatment of proteinuria: astragalus,
coptidis, Flastem Milkvetch Seed, Gordon Euryale Seed
and Cherokee Rose Fruit (the Latin name and English
name of the Chinese herbs mentioned in the article are
shown in Table 1).
One of the most obvious inconveniences of TCM is the
preparation. It is very difficult to ask patients to decoct
TCM several times daily for a long time and, therefore, this
research group decided to make the formula in the form of
granules (the ingredients are shown in Table 1). The
granules are processed using the following methods: first,
coptidis is ethanol extracted; second, the other five herbs
are decocted together and then aqueous extracted; third,
the concentrate from the previous two steps is mixed and
then spray-dried. The granule is a 10 g/package.
Table 1 Traditional Chinese Medicinal Herbs used in Huang Qi Elixir formula/granule
PinYin name Latin name English name Daily decoction dose Dose per 1,000 g granule
Huangqi Radix Astragali Astragalus/Astragalus membranaceus 30 g 500g
Shayuanzi Semen Astragali Complanati Flastem Milkvetch Seed 30 g 500g
Huanglian Rhizoma Coptidis Golden Thread 10 g 167g
Jinyingzi Fructus Rosae Laevigatae Cherokee Rose Fruit 15 g 250g
Qianshi Semen Euryales Gordon Euryale Seed 15 g 250g
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The aim of this clinical study is: (1) to evaluate if the efficacy
of Huang Qi Elixir for proteinuria in patients with
microalbuminuria is equivalent to that of the decoction; (2)
to establish the working dose of the TCM granule; and (3)
to evaluate the difference in efficacy between the TCM
granule and the ARB (that is, irbesartan).
Methods/design
Design
This pilot study is a randomized, controlled, multi-center,
clinical trial. The study will be sequentially conducted as
follows: enrollment after screening via inclusion and
exclusion criteria; randomization; a treatment period
of 12 weeks; and assessment. The flow chart of the
study is shown in Figure 1.
Participants and eligibility
Inclusion criteria
To be included in the study, patients must have:
1. symptoms of diabetes and a casual plasma glucose
≥11.1 mmol/L or fasting plasma glucose ≥7.0 mmol/LFigure 1 Flow chart of the clinical study.or in a oral glucose tolerance test, two-hour plasma
glucose ≥11.1 mmol/L;
2. 30 mg/g < albumin-to-creatinine ratio (ACR)
<300 mg/g or 30 mg/24hour <24 hour UAE
<300 mg/24 hour, and GFR ≥40ml/min;
3. an age of 18 to 75 years;
4. acceptable glycemic control (FPG ≤10.0 mmol/L or
postprandial plasma glucose ≤12 mmol/L and
HbA1c ≤8.5%);
5. tolerablity to ARBs and blood pressure (BP)
<150/90 mm Hg;
6. plasma albumin ≥30g/L
7. provided written informed consent.
The first two criteria must be met simultaneously.
Exclusion criteria
Patients will be excluded if they have any of the
following:
1. diabetes mellitus concurrent with non-diabetic
kidney disease or are kidney transplant recipients;
2. concurrent severe disorders of heart, brain, liver or
the hematopoietic system;
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4. mental disorders;
5. intolerance to oral medications or severe
malabsorption;
6. hepatic dysfunction or a value of transaminase
higher than one and a half times the upper limit;
7. allergy to TCM/ARBs or other allergies;
8. uncontrollable urinary infection or infections which
influence the measurement of urinary protein;
9. pregnancy or lactation;
10.participation in other clinical trials within the past
thirty days; and
11.anticipated survival <1 year.
Recruitment
There are six centers involved in this clinical trial
and participants will be recruited via posters at each
participating center.
Randomization and intervention
The study has four arms. After enrollment, 48 participants
who meet the inclusion criteria will be randomly assigned
to either: 1) granule group, 10 grams three times daily
(G10 group, n = 12); 2) granule group, 20 grams three
times daily (G20 group, n = 12); 3) the decoction
group (D group, n = 12); or 4) the irbesartan group
(Aprovel group, n = 12). The treatment course is 12
weeks. The randomization sequence will be generated
with an SAS software package by the Good Clinical
Practice (GCP) Center of the Teaching Hospital of
Chengdu University of TCM and will be concealed
and disseminated using opaque envelopes.
Outcome measures
Primary outcome
The primary outcome, percentage change in ACR from
baseline, will be measured at week 12. ACR will be
measured with a spot urine test, every four weeks; 15
to 20 ml spot urine samples will be collected at each
visit to assess albuminuria.
Secondary outcomes
The secondary outcomes include changes in GFR,
Scr, HbA1c, urinalysis and FPG. All of these will be
measured every four weeks except for HbA1c, which
will be measured at week 12 only.
Statistical methods
Statistical analyses will be conducted based on an
intention-to-treat population. Participants who take at
least one dose of drug and have one value on treatment
comprise the full-analysis set (FAS) and those who
complete a 12-week treatment comprise the per-protocol
set (PPS). Missing data will be imputed with the use of thelast-observation-carried-forward method, whereby missing
values will be replaced by the last non-missing value.
Repeated measures and multivariate analysis of variance
of the general linear model will be applied to determine
the changes in GFR, Scr and FPG at each visit. Percentage
reduction from baseline in ACR and changes from base-
line in HbA1c will be summarized and comparisons will
be made by using a one-way analysis of variance.
Compliance
Establishment of TCM and irbesartan after each visit will
be quantified in order to enhance medication compliance.
Participants whose compliance with TCM or irbesartan
is < 80% of the total dose will be considered to have
dropped out.
Adverse events
All adverse events related to TCM and irbesartan will be
reported to the ethics committee of the Teaching Hospital
of Chengdu University of Traditional Chinese Medicine
and also to each participating center in written case
report form. Safety will be monitored using routine
blood examination, liver and renal function, blood electro-
lytes and electrocardiogram (ECG). Other potential adverse
events will be clearly documented and followed up until
they are resolved or alleviated.
Sample size
Each arm will only include 12 subjects, for this is just a
pilot trial aimed at exploring some parameters for a
future clinical trial with a large sample size.
Ethics
The study protocol and the written informed consent
were approved by the Sichuan Regional Ethics Review
Committee on Traditional Chinese Medicine (2012KL-013).
Written informed consent will be obtained from each
patient.
Discussion
Many clinical trials have been carried out to evaluate the
efficacy of TCM for DN [14,15]. Liu et al. [16] systematic-
ally reviewed randomized controlled trials evaluating the
efficacy and safety of astragalus in the treatment of DN.
Their results included 33 RCTs and one quasi-RCT involv-
ing 2,356 patients and showed that it ‘had some effects on
the decrease of the 24-hour urinary albumin excretion rate
(UAER), 24-hour urinary protein, Scr, and BUN, and also
on the improvement of Ccr’ (p. 727). They concluded that
it ‘has some effect and is relatively safe in treating patients
with DN’. Another study [17] evaluated the efficacy and
safety of a TCM capsule, Xuezhikang, in the treatment of
DN. The results of meta-analyses showed that it ‘was super-
ior to routine treatment in decreasing 24-h urinary protein,
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risk of selection bias and detection bias in the included
studies, the evidence is insufficient to determine the effect
of Xuezhikang’.
Obviously, it is notable that most published clinical
trials which assessed the efficacy of TCM on DN were of
poor methodology, and, therefore, their results have been
invalidated. It is necessary to carry out well-designed
clinical trials to provide sound evidence. The present
clinical study introduces those promising and classical herbs
and formulae into the treatment of microalbuminuria. To
make administration convenient, a TCM decoction will be
processed in the form of granules. The present trial is a
study of great value for it will provide important parameters
for a future randomized, placebo-controlled, clinical trial
with a large sample size.Trial status
Patient recruitment for the trial is on-going. Data collection
will continue until the end of 2013.Abbreviations
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